Invivyd (IVVD) Receivables - Net (2024 - 2025)
Invivyd (IVVD) posted Receivables - Net of $13.9 million for Q4 2025, up 41.28% on a QoQ basis from $9.9 million in Q3 2025, and up 27.63% year-over-year from $10.9 million in Q4 2024.
Invivyd (IVVD) Receivables - Net (2024 - 2025) Analysis & Trends
Invivyd's Receivables - Net history runs 2 years deep, the most recent figure standing at $13.9 million for Q4 2025.
- Quarterly Receivables - Net rose 27.63% year-over-year to $13.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $13.9 million (up 27.63% YoY) and the FY2025 annual result came in at $13.9 million, up 27.63% from the prior year.
- Receivables - Net was $13.9 million for Q4 2025 at Invivyd, up from $9.9 million in the prior quarter.
- Across five years, Receivables - Net topped out at $13.9 million in Q4 2025 and bottomed at $2.9 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Invivyd | 104.07 Mn | -122.62 Mn | 16.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 13.92 Mn |
| Dec 31, 2025 | 13.92 Mn |
| Sep 30, 2025 | 9.85 Mn |
| Sep 30, 2025 | 9.85 Mn |
| Jun 30, 2025 | 8.70 Mn |
| Jun 30, 2025 | 8.70 Mn |
| Mar 31, 2025 | 8.56 Mn |
| Mar 31, 2025 | 8.56 Mn |
| Dec 31, 2024 | 10.91 Mn |
| Dec 31, 2024 | 10.91 Mn |
| Sep 30, 2024 | 8.20 Mn |
| Sep 30, 2024 | 8.20 Mn |
| Jun 30, 2024 | 2.90 Mn |
| Jun 30, 2024 | 2.90 Mn |